LMNX Luminex Corp.

All LMNX filings Filing statistics SEC Website

Luminex Corp. develops, manufactures and markets proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The company was founded by Mark B. Chandler and Van S. Chandler in May 1995 and is headquartered in Austin, TX.

Company profile

Ticker

LMNX

Exchange

NASDAQ

CEO

Nachum Shamir

Incorporated in

Delaware

Location

Texas

Fiscal year end

Dec 31

Sector

Health Technology > Biotechnology

Industry (SEC)

Surgical & Medical Instruments & Apparatus

3M • Baxter International • Stryker • ResMed • Integra LifeSciences • Haemonetics • Hill-Rom • NuVasive • Merit Medical Systems • Globus Medical ...

SEC CIK

0001033905

Corporate docs

Articles of Incorporation & Bylaws

IRS number

742747608

LMNX stock data

S&P 500 1 month 1 year

Company financial data Financial data

Chart LMNX financial data

Download latest Excel data (2019 Q1) View latest Excel data (2019 Q1)

Quarter (USD)	Mar 19	Dec 18	Sep 18	Jun 18
Revenue	82.41M	81.13M	72.45M	79.58M
Net income	2.96M	-2.3M	1.74M	5.67M
Diluted EPS	0.07	-0.05	0.04	0.13
Net profit margin	3.59%	-2.83%	2.40%	7.12%
Operating income	-3.58M	968K	3.75M	7.86M
Net change in cash	-14.75M	-70.45M	7.9M	10.34M
Cash on hand	61.69M	76.44M	146.89M	139M
Cost of revenue	36.6M	32.79M	28.19M	30.27M

Annual (USD)	Dec 18	Dec 17	Dec 16	Dec 15
Revenue	315.82M	306.57M	270.64M	237.71M
Net income	18.51M	29.42M	13.81M	36.86M
Diluted EPS	0.41	0.67	0.32	0.86
Net profit margin	5.86%	9.60%	5.10%	15.51%
Operating income	27.85M	37.15M	20.99M	37.36M
Net change in cash	-50.67M	33.66M	-35.09M	36.85M
Cash on hand	76.44M	127.11M	93.45M	128.55M
Cost of revenue	120.33M	107.53M	90.98M	69M

Financial data from Luminex earnings reports

Financial report summary

Competition

Abbott Laboratories • PerkinElmer, Inc. • Thermo Fisher Scientific • Danaher • Quidel • Accelerate Diagnostics • Life • Danaher • Meridian Bioscience • Hologic

Management Discussion

Total revenue was $82.4 million for the three months ended March 31, 2019, down slightly from $82.7 million for the comparable period in 2018. The Company experienced a decrease in our non-automated assay revenue, mainly attributable to the decrease in LabCorp sales. These decreases were largely offset by the addition of our newly acquired flow cytometry business, which comprised 14% of total revenue in the first quarter of 2019, as well as increases in our automated assay revenue. Non-automated assay revenue comprised 48% of total assay revenue for the three months ended March 31, 2019 compared to 68% for the comparable period in 2018. Automated assay revenue, which consists of VERIGENE and ARIES® assays, grew 15% to more than $17.1 million for the three months ended March 31, 2019 from the comparable period in 2018.

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absolute, achieve, added, adding, affiliate, affordable, agreed, answer, area, attaching, authorization, benchtop, bind, biochemical, biomarker, borrowing, bringing, capture, captured, cease, cell, CellStream, centered, challenge, coated, color, colored, commencement, competing, consecutive, counting, create, customizable, cytometer, database, derived, discount, displayed, distinctly, driver, dye, easyCyte, ELISA, engineering, enzymatic, escalation, FlowSight, fluorescence, fluorescent, foregoing, Gen, highest, hour, ImageStream, immunologic, implicit, InCyte, inexpensive, injected, innovative, IRS, KgaA, laser, legislation, lighter, magnetic, maximum, mentioned, Merck, merit, microarray, microcapillary, microscopy, microsphere, microtiter, milestone, MilliporeSigma, mixture, Muse, nonrecurring, package, panel, particle, percent, plant, plate, polystyrene, preliminary, produce, reassessing, recruit, reliance, rent, retired, scalable, signature, simple, simplified, slightly, solution, space, spatial, speed, spite, stored, talent, technical, tenant, track, trend, tube, type, underway, versatile, vesting, viability, Washington, wholly

Removed: annually, AOCI, arise, ASU, audit, Australian, backed, bought, Bulletin, calculate, claimed, commercializing, commit, comparative, constrained, content, Cystic, declined, deemed, delivery, depending, depreciation, disposable, diversity, eliminating, evaluated, exceeded, extension, fewer, field, fifteen, finalized, forecasted, fourth, frequently, fulfillment, functionality, GILTI, handling, impractical, incorporated, industry, installation, integrated, interpretation, law, marketable, maturity, minimum, month, mortgage, negotiated, October, offered, originally, permanent, policy, practice, prepay, prepayment, principally, promise, promissory, purpose, reclassified, reclassify, recognizing, reduce, refine, refinement, registrant, reinvestment, relevant, remeasured, remeasurement, represented, requirement, restated, reversal, reverse, SAB, secondary, settled, shipment, shipped, shown, sourced, step, stranded, temporary, Topic, trading, treat, treated, twenty, ultimate, ultimately, understanding, unit

From filing 10-Q 2019 Q1